| 51 |
30683066 | Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review. | 2019 Jan 25 |
2 |
| 52 |
30713295 | Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. | 2019 Jun 1 |
5 |
| 53 |
30718357 | Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. | 2019 Feb 15 |
1 |
| 54 |
30735003 | Mixed response to osimertinib and the beneficial effects of additional local therapy. | 2019 Apr |
2 |
| 55 |
30774361 | Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review. | 2019 |
4 |
| 56 |
30788361 | Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. | 2019 Jan |
3 |
| 57 |
30796031 | On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. | 2019 Jun 1 |
4 |
| 58 |
30809659 | Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). | 2019 Jun 1 |
4 |
| 59 |
30819142 | Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report. | 2019 Feb 28 |
3 |
| 60 |
30821083 | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. | 2019 Apr |
2 |
| 61 |
30828454 | Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. | 2019 Apr |
1 |
| 62 |
30847464 | Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. | 2019 May 1 |
2 |
| 63 |
30856555 | The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. | 2019 May |
11 |
| 64 |
30863108 | First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. | 2019 |
5 |
| 65 |
30863565 | Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer. | 2019 Jan |
1 |
| 66 |
30864019 | Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. | 2019 Oct |
2 |
| 67 |
30864291 | Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. | 2019 Apr |
1 |
| 68 |
30872380 | TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X. | 2019 May |
1 |
| 69 |
30872388 | Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. | 2019 May |
2 |
| 70 |
30875094 | Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. | 2019 Aug |
5 |
| 71 |
30875919 | Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. | 2019 Mar 15 |
8 |
| 72 |
30875928 | Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? | 2019 Mar 15 |
4 |
| 73 |
30876460 | Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. | 2019 Mar 15 |
1 |
| 74 |
30881166 | Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification. | 2019 |
2 |
| 75 |
30901844 | Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. | 2019 Mar 21 |
3 |
| 76 |
30905617 | Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). | 2019 May |
2 |
| 77 |
30906765 | Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer. | 2019 Feb |
1 |
| 78 |
30916819 | Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S. | 2019 Aug |
4 |
| 79 |
30930332 | Combo Therapy Beats Back Relapsed NSCLC. | 2019 Jun |
3 |
| 80 |
30941723 | Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment. | 2019 Jun |
3 |
| 81 |
30997189 | Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. | 2019 Mar |
1 |
| 82 |
30997245 | The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. | 2019 Mar |
2 |
| 83 |
31014050 | [Mechanism of MALAT1 induced osimertinib resistance in HCC827 lung cancer cells]. | 2019 Apr 23 |
2 |
| 84 |
31027702 | From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. | 2019 May |
1 |
| 85 |
31029076 | Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. | 2019 Apr 27 |
1 |
| 86 |
31033571 | Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer. | 2019 May 5 |
1 |
| 87 |
31039766 | The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. | 2019 Apr 30 |
2 |
| 88 |
31043566 | Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. | 2019 May 14 |
1 |
| 89 |
31043587 | AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. | 2019 May 1 |
1 |
| 90 |
31099642 | Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. | 2019 Jan |
1 |
| 91 |
31119481 | Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. | 2019 Jun |
1 |
| 92 |
31138260 | Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. | 2019 May 28 |
8 |
| 93 |
31183356 | Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. | 2019 May 26 |
5 |
| 94 |
31205925 | EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib. | 2019 May |
3 |
| 95 |
31213907 | Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. | 2019 |
6 |
| 96 |
31228625 | Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor. | 2019 Oct |
2 |
| 97 |
31235042 | Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation. | 2019 Jul |
1 |
| 98 |
31261881 | Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. | 2019 Jun 29 |
4 |
| 99 |
31262922 | Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib? | 2019 Jul |
2 |
| 100 |
31265163 | Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. | 2019 Sep |
1 |